EU/3/16/1798

About

Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in October 2019 on request of the Sponsor.


On 12 December 2016, orphan designation (EU/3/16/1798) was granted by the European Commission to Merck Serono Europe Limited, United Kingdom, for avelumab for the treatment of gastric cancer.

The sponsorship was transferred to Merck Europe B.V., The Netherlands, in June 2018.

Key facts

Active substance
avelumab
Disease / condition
Treatment of gastric cancer
Date of first decision
12/12/2016
Outcome
Withdrawn
EU designation number
EU/3/16/1798

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Merck Europe B.V.
Gustav Mahlerplein 102
lto Toren
1082 MA Amsterdam
The Netherlands
Tel. +31 2065 80548
E-mail: service@merckgroup.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating